Pro-Pharmaceuticals ships foremost commercial grouping of DAVANAT to PROCAPS in Colombia

Pro-Pharmaceuticals, Inc. (OTC: PRWP), the prime developer of therapeutics that target Galectin receptors to premium cancer and fibrosis, today announced it has shipped its first commercial order of DAVANAT® to PROCAPS S.A., a corpulent, oecumenical pharmaceutical suite based in Barranquilla, Colombia. The $200,000 shipment of DAVANAT® will be acclimated to by PROCAPS to meet the requirements its vial filling process.

“PROCAPS is an extraordinary friend to commercialize DAVANAT® in Colombia as robust as in other countries in Latin America. PROCAPS operates later on in ten Latin American countries and more than 30 countries worldwide, exporting pharmaceutical and supplementation products and has a document of success launching fresh products”

This firstly commercial shipment of DAVANAT® is a biggest milestone repayment for our Party, said Theodore D. Zucconi, Ph.D., Chief Chief Officer, Pro-Pharmaceuticals. We suffer with herpes cure Acyclovir been to a great extent weigh in delightful into caring the variables associated with first-time, foreign shipments of pharmaceutical products.

PROCAPS is an excellent alter ego to commercialize DAVANAT® in Colombia as well as in other countries in Latin America. PROCAPS operates speedily in ten Latin American countries and more than 30 countries worldwide, exporting pharmaceutical and addendum products and has a record of attainment launching modern products, said Zucconi.

Earlier this year, Pro-Pharmaceuticals granted PROCAPS exclusive rights to market and drummer DAVANAT® to treat cancer in Colombia, South America. As participation of the Compact, PROCAPS is stable on the blessing treat, as well as issuance, marketing and sales of DAVANAT® in Colombia. Regulatory endorsement to merchandise and sell DAVANAT® is expected in the elementary quarter of 2011.